This inventor holds 2 USPTO granted patents. Top assignees: Amgen Inc., Synergen Biologicals, Inc.. Active years: 1988-1999.
Location History:
- Glemmingebro, SE (1988)
- Glemminge Prastgard, SE (1999)
Company Filing History:
Years Active: 1988-1999
Title: Kjell Ohlsson: Innovator in Serine Protease Inhibitors
Introduction
Kjell Ohlsson is a notable inventor based in Glemminge Prastgard, Sweden. He has made significant contributions to the field of biochemistry, particularly in the development of serine protease inhibitors. With a total of 2 patents, Ohlsson's work has implications for various therapeutic applications.
Latest Patents
Ohlsson's latest patents include innovative analogs of serine protease inhibitors. These analogs feature slight variations in their amino acid sequences, which enhance their properties. They demonstrate improved resistance to oxidative inactivation and exhibit enhanced abilities to inhibit pancreatic elastase, cathepsin G, and trypsin. Another significant patent involves a purified serine protease inhibitor protein. This protein is characterized by a single-polypeptide-chain structure with at least one active site that possesses serine protease inhibitor activity. It shows substantial homology to the native serine protease inhibitor found in parotid secretions and is resistant to heat, acids, and proteolytic enzymes. Additionally, this inhibitor can re-fold into an active form after denaturation, showcasing its robustness.
Career Highlights
Throughout his career, Kjell Ohlsson has worked with prominent companies in the biotechnology sector. He has been associated with Synergen Biologicals, Inc. and Amgen Inc., where he contributed to various research and development projects. His expertise in serine protease inhibitors has positioned him as a valuable asset in these organizations.
Collaborations
Ohlsson has collaborated with several professionals in his field, including Robert C. Thompson. These collaborations have furthered the research and development of serine protease inhibitors, leading to advancements in therapeutic applications.
Conclusion
Kjell Ohlsson's innovative work in serine protease inhibitors has made a significant impact in biochemistry. His patents reflect a commitment to enhancing the properties of these inhibitors, which may lead to important therapeutic advancements.